AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants...
- Mechanism
- Curator reviewed
AME-527 is approximately ten-fold more potent than Remicade(R) in binding to and neutralizing the hTNF-alpha molecule, and 6 to 8-fold more potent than Humira(TM). Tumor necrosis factor-alpha (TNF-alpha) has a key role in rheumatoid synovitis, as an inflammatory cytokine at the top of the inflammatory cascade. Blocking TNF-alpha with AME-527 or fusion proteins is an important and established disease intervention, validating the role of the cytokine in disease activity and progression.
- Primary indication
- Investigated for use/treatment in rheumatoid arthritis.Curator reviewed
- Code names
- AME-527
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with AME-527, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account